Objective To investigate the efficacy of Qiju Dihuang pill combined with fluorometholone eye drops on dry eye disease(DED)due to Yin deficiency of liver and kidney and its impact on the ocular surface function of patients.Methods Ninety-two patients with DED admitted to our hospital from April 2021 to May 2024 were gathered and assigned into two groups using a random number table method,with 46 patients in each group.The conventional group was treated with fluorometholone eye drops,while the combination group was treated with Qiju Dihuang pills on the basis of the conventional group.The efficacy,tear film break up time(TBUT),length of tear infiltration,corneal fluorescein staining(FLS)and ocular surface disease index(OSDI)of DED patients were compared between the two groups,and adverse reactions were evaluated.Results After treatment,the length of TBUT and tear infiltration were significantly increased in the two groups(P＜0.05),OSDI and FLS scores were significantly decreased(P＜0.05),and changes were more significant in the combined group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).The efficacy of the combination group was 91.30%(42/46),which was higher than that of the conventional group,76.09%(35/46)(P＜0.05).Conclusion The combination of Qiju Dihuang pill and flumilone eye drops has good therapeutic effect for patients with DED of Yin deficiency of liver and kidney.

Objective To investigate the efficacy of Qiju Dihuang pill combined with fluorometholone eye drops on dry eye disease(DED)due to Yin deficiency of liver and kidney and its impact on the ocular surface function of patients.Methods Ninety-two patients with DED admitted to our hospital from April 2021 to May 2024 were gathered and assigned into two groups using a random number table method,with 46 patients in each group.The conventional group was treated with fluorometholone eye drops,while the combination group was treated with Qiju Dihuang pills on the basis of the conventional group.The efficacy,tear film break up time(TBUT),length of tear infiltration,corneal fluorescein staining(FLS)and ocular surface disease index(OSDI)of DED patients were compared between the two groups,and adverse reactions were evaluated.Results After treatment,the length of TBUT and tear infiltration were significantly increased in the two groups(P＜0.05),OSDI and FLS scores were significantly decreased(P＜0.05),and changes were more significant in the combined group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).The efficacy of the combination group was 91.30%(42/46),which was higher than that of the conventional group,76.09%(35/46)(P＜0.05).Conclusion The combination of Qiju Dihuang pill and flumilone eye drops has good therapeutic effect for patients with DED of Yin deficiency of liver and kidney.

Objective:The aim is to construct an evaluation framework for clinical research benefits,and provide a reference for the formulate of evaluation standards for clinical research benefits.Methods:The Delphi method was used to carry out expert consultation,and the mean,score of importance,coefficient of variation and coordination,etc.of evaluation indicators were summarized and calculated,to screen evaluation indicators for clinical research benefits.Results:Twenty-three experts in this field were selected for correspondence,and their enthusiasm was 100%in both rounds,the authority coefficients were≥0.90,and Kendall's coefficients of concordance were<0.25(P<0.001).By referring to the mean and coefficient of variation of the indicators,as well as combining them with expert suggestions,an evaluation framework for clinical research benefits was ultimately formed with 2 primary indicators,5 secondary indicators,and 8 tertiary indicators.Conclusion:The evaluation framework for clinical research benefits constructed in this paper can comprehensively evaluate the research benefits,as well as provide a basis for reasonably determining the research risk-benefit ratio and developing quantitative evaluation tools for clinical research benefits.